tislelizumab
novartis,beigene
[]
os curves from rationale-305 in 5% pd-l1 expressers don't leave much hope for a result in all-comers. ultimately a smartly thought-through statistical analysis plan $bgne $nvs #gi23 
Journalist at Evaluate Vantage. Proudly blocked by @JohnCendpts. Interested in: oncology, immunology. Not interested in: what stock you bought today.